AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01516957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 827 280
Description: 280 mg AMG 827 SC (subcutaneous)
Study NCT01516957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 827 210
Description: 210 mg AMG 827 SC (subcutaneous)
Study NCT03155074 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity training
Description: The exercise program will include a cardiovascular warm-up, high intensity interval training and progressive resistance training (PRT). The intervention will focus on high-intensity training, mainly by uphill walking on a treadmill at 80-95 % of the maximal heart rate and PRT in three series at 6-12 RM by leg press, chest press, back extension, seat row, and front raises. During the first four weeks, the patients will be introduced to the program while focusing on safety, techniques and familiarization. The endurance intensity and strength load will then continuously increase based on the patients' improvement, tolerance of dyspnea, and feelings of well-being or fatigue on each exercise day.
Study NCT02132767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Amiodarone Initial Dose~* Oral: 400 mg po TID for 3 days is recommended~* For patients incapable of taking oral: 150 mg IV bolus over 10 min, then 1 mg/min over 6 hours followed by 0.5 mg/min over 18 hours Maintenance Dose~* Oral: at least 200 mg/day to be continued until 60 days after randomization~* If drug cannot be given orally or via NG tube: 0.5 mg/min administered through central line (e.g., PICC) until oral dosing is started
Study NCT02132767 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DC-cardioversion
Description: DC-Cardioversion - frequency and duration determined by medical professional as medically needed
Study NCT02132767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rate Control
Description: Beta-blocker and/or Calcium channel blockers and/or Digoxin - Dose, frequency and duration determined by medical professional as medically needed
Study NCT01991158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of methotrexate
Description: Methotrexate 3.0g/Kg, intravenous drip D1
Study NCT01991158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1g/m2 intravenous drip D1,D8
Study NCT01991158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Pegaspargase 2500U/m2 intramuscular injection (IM) D1
Study NCT01991158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20mg/d intravenous drip D1, po D2-3
Study NCT03131336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PeproStat
Description: solution for local application
Study NCT03131336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: solution for local application
Study NCT02681510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Standard FDA approved 12 weeks of treatment with Varenicline
Study NCT02681510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Transdermal Patch
Description: Standard FDA approved 12 weeks of treatment with Nicotine Transdermal Patch
Study NCT02681510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Mini
Description: Standard FDA approved 12 weeks of treatment with Nicotine Mini-Lozenge
Study NCT00270855 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Arm Crank Ergometry
Description: Use of an upper body cycle to perform exercise. 10-minute warm up, 40 minutes @ 70%HRMax (50RPM), 10 minute cool down 5x/week x 16 weeks
Study NCT00270855 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: FES Cycle Ergometer
Description: Use of an FES cycle ergometer to perform exercise. 10-minute warm up, 40 minutes @ 70%HRMax (50RPM), 10 minute cool down 5x/week x 16 weeks
Study NCT02234102 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopically guided laser ablation HeartLight system
Study NCT02091024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ECE (Ecklonia cava extract)
Description: ECE 200mg, twice a day
Study NCT02091024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 200mg, twice a day
Study NCT04677101 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Liver Biopsy
Description: Fine-needle liver biopsy
Study NCT01185197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myfortic plus low-dose steroid
Description: Prednisolone: 0.25 mg/kg/day for 8 weeks then 0.15 mg/kg/day for 8 weeks then 0.1 mg/kg/day for 8 weeks then off Myfortic: 720 mg b.i.d. (540 mg b.i.d. if body weight less than 60 kg) for 24 weeks then off
Study NCT01185197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: 1 mg/kg/day to be tapered over a period of 24 weeks at the discretion of the attending physician
Study NCT01749202 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sunflower Oil Softgels
Description: 3 x 500 mg softgel capsules/day
Study NCT01749202 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sunflower Oil Softgels
Description: 3 x 500 mg softgel capsules/day
Study NCT01749202 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EPA softgels
Description: 3 x 500 mg softgel capsules/day
Study NCT01749202 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sunflower Oil Food
Description: 3 servings/day
Study NCT01749202 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sunflower Oil Food
Description: 3 servings/day
Study NCT01749202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SDA soybean Oil Food
Description: 3 servings/day
Study NCT04201730 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery （ERAS）
Description: Preoperative education，Preoperative nutritional support，Preoperative bowel preparation，Preventative applying of antibiotics，Intraoperative warming，Goal-directed fluid therapy，Postoperative analgesia，Postoperative diet, drainage and activity management，Prevention of deep vein thrombosis.
Study NCT04141982 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: T-Cell SelectTM Kit
Description: The T-Cell Select kit is intended for the isolation of mononuclear immune cells from whole blood, using positive selection via a magnetic bead-based cell separation system, for use in the T-SPOT.TB assay.
Study NCT02879344 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood draw
Study NCT01867879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: 35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
Study NCT01968564 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: sugar and other inert substances
Study NCT01968564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose curcumin pill
Description: 2000mg curcumin pill/day
Study NCT01968564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose curcumin pill
Description: 500mg curcumin pill/day
Study NCT01867879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, orally, single dose.
Study NCT03293251 — intervention group
Intervention type: PROCEDURE
Intervention: Trabeculectomy with MMC
Description: glaucoma surgeries
Study NCT01980043 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: endoluminal rectal prolapse repair under sedation
Description: endoluminal rectal prolapse repair under sedation
Study NCT04630951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Strength training with low load
Description: Low Load (20-50% 1RM), 4 set of 30/15/15/15 repetitions, 30 seconds resting between sets.
Study NCT04630951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Load Strength Training
Description: High Load (60-80% 1RM) 4 sets of 8 repetitions, 2 minutes resting between sets
Study NCT04588649 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: THK-5351
Description: \[18F\]THK-5351 PET Imaging
Study NCT04588649 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AV-45
Description: \[18F\]AV-45 PET Imaging
Study NCT06582836 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The objective of the study was to investigate the effect of prior engagement of tooth with orthodontic appliance on post extraction pain among orthodontic patients
Description: In this randomized clinical trial, 44 patients were recruited who needed bilateral extractions of first premolars in upper arches. Patients were divided into two groups based on the timing of extractions. Group A needed extractions before alignment while Group B needed extractions for retraction of anterior teeth. Group A was sent for extractions first while Group B went for orthodontic bonding and banding procedures for orthodontic treatment. After series of aligning wires (0.014, 0.016, 17x25, 19x25 Heat activated NiTi and 19x25 SS) patients from group B were sent for extractions. For pain assessment, an 11-point numerical rating scale (NRS) were given to record pain intensity at 2, 4, 8, 12 and then 24 hours after extraction for the next 7 days.
Study NCT01108627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: open-labeled inhaled corticosteroids (ICS); FORADIL® AEROLIZER®
Description: • Drugs. The study drugs are open-labeled inhaled corticosteroids (ICS); FORADIL® AEROLIZER® and FORADIL placebo. FORADIL® AEROLIZER® consists of a capsule dosage form containing a dry powder formulation of FORADIL (formoterol fumarate) intended for oral inhalation only with the AEROLIZER Inhaler. Each clear, hard gelatin capsule contains a dry powder blend of 12 mcg of formoterol fumarate and 25 mg of lactose (which contains trace levels of milk proteins) as a carrier. Ten capsules are contained in each package, which is clearly labeled. To use the delivery system, a FORADIL capsule is placed in the well of the AEROLIZER Inhaler, and the capsule is pierced by pressing and releasing the buttons on the side of the device. The formoterol fumarate formulation is dispersed into the air stream when the patient inhales rapidly and deeply through the mouthpiece.
Study NCT01108627 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: foradil placebo
Description: open-labeled inhaled corticosteroids (ICS); foradil placebo
Study NCT01108627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: foradil
Description: open-labeled inhaled corticosteroids (ICS); foradil
Study NCT05416242 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional braces
Description: MBT 0.022 perception traditional braces will be used without any acceleration method.
Study NCT05416242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-ligating braces
Description: MBT 0.022 perception Self-ligating braces will be used without any acceleration method.
Study NCT05416242 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-ligating braces + piezocision
Description: Flapless corticotomy will be applied for the upper anterior teeth.
Study NCT04005066 — intervention group
Intervention type: DRUG
Intervention: Elunate®
Description: The recommended dose is 5 mg once daily (1 capsule, each capsule contains 5 mg of fruquintinib); three weeks of continuous drug administration followed by one week of drug free period (4 weeks as one treatment cycle).
Study NCT03332810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SME family based physical activity
Description: * One train-the-trainer workshop: to train the service providers from 8-15 NGO service units on the concept of SME, ways of conducting mental well-being activities and knowledge of adult mental health problem (in particular the mixed anxiety and depressive disorder).~* Two SME family-based physical activities held by each NGO service unit: to organize enjoyable activities according to the needs of individual district as well as to promote positive psychology under the theme of SME. All these activities are organized by the NGO service providers in collaboration with District Healthy City Committee.
Study NCT03332810 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gathering activity
Description: - Gathering activities will be held for control groups. However, SME concept or techniques will not be introduced during the activity. Physical activity will not be used as the intervention method.
Study NCT05151289 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood test at time of inclusion for sFlt-1/PlGF ratio
Description: As part of the research, a blood sample is taken to measure the sFLT-1 and PlGF ratio at the inclusion visit.
Study NCT05151289 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Follow-up blood test 2 to 4 weeks after inclusion
Description: As part of the research, a blood sample is taken to measure the sFLT-1 and PlGF ratio at the follow-up visit (about 2-4 weeks after inclusion). This second sample is not mandatory for the evaluation of the study's main endpoint.
Study NCT05151289 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Placenta analysis for all included patients, even in case of normal birthweight
Description: After delivery, the placenta of each included patient is sent to anatomo-pathology (even in case of normal weight of the baby at birth). An anatomopathologist referent, designated for the study in each center, performs an analysis (aware of the clinic but not of the sFLT-1/PlGF ratio results), according to the benchmark criteria grid. Local analysis will classify the placenta as vascular IUGR or nonvascular IUGR.
Study NCT04160624 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcatheter aortic valve replacement
Description: Use Venus-A valve or J-Valve to perform TAVR procedure. Use cardiopulmonary bypass or cardiopulmonary bypass to provide ECLS
Study NCT04160624 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transcatheter aortic valve replacement
Description: Use Venus-A valve or J-Valve to perform TAVR procedure. Use cardiopulmonary bypass or cardiopulmonary bypass to provide ECLS
Study NCT02129608 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LLLT
Description: The LLLT uses 6 diode laser heads - each emitting 17 mW output. Subject will receive 30 minutes of therapy in the frontal central area and 30 minutes of therapy in the back central area, once a week for 12 weeks.
Study NCT02129608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorcaserin
Description: 10 mg pills twice daily for 12 weeks.
Study NCT02604407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP465 12.5mg capsules (one capsule daily)
Description: one capsule daily
Study NCT02604407 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsule that appears identical in size, weight, shape, and color (one capsule daily)
Study NCT02604407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP465 12.5mg, 25mg, or 37.5mg capsules (one capsule daily)
Description: One capsule daily
Study NCT03094637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV
Study NCT03094637 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02715011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63709178
Description: Participants will receive JNJ-63709178 in Part 1 and Part 2.
Study NCT04019626 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continue-smoking
Description: Ad-libitum use of subjects' usual brand combustible cigarette
Study NCT02196259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthetics, Dissociative
Description: The subject will receive intravenous anesthesia at a dose of 0.5mg/kg delivered over 40 minutes in a constant infusion or bolus plus infusion method to maintain steady state (10 minutes initial induction, 30 minutes steady-state, for 40 minutes total)
Study NCT01811459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: PO
Study NCT01811459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: IV
Study NCT01811459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PO or IV
Study NCT04019626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myblu Tobacco 2.5%
Description: Ad-libitum use of myblu e-cigarette with Tobacco flavor 2.5% nicotine
Study NCT04019626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myblu Tobacco 4.0%
Description: Ad-libitum use of myblu e-cigarette with Tobacco flavor 4.0% nicotine
Study NCT04019626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myblu Honeymoon 2.5%
Description: Ad-libitum use of myblu e-cigarette with Honeymoon flavor 2.5% nicotine
Study NCT04019626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myblu Honeymoon 4.0%
Description: Ad-libitum use of myblu e-cigarette with Honeymoon flavor 4.0% nicotine
Study NCT04019626 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: JUUL 5%
Description: Ad-libitum use of JUUL 5% e-cigarette
Study NCT03551821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-50002
Description: Topical Solution
Study NCT01271218 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Participants followed isoenergetic low fat diets with higher protein (HP) or higher carbohydrate (HC) macronutrient content. Participants consumed 1,200 kcals/d for 1-week (Phase I) and 1,600 kcals/d for 9-weeks (Phase II) during a 10-week weight loss period. Participants in the HC diet consumed a diet containing 55% carbohydrate, 15% protein, and 30% fat. Subjects in the HP group consumed a diet containing 7% carbohydrate, 63% protein, and 30% fat during Phase I of the diet and 15% carbohydrate, 55% protein, and 30% fat during Phase II of the diet. The final 4-weeks of the diet (Phase III) served as a weight maintenance period in which participants consumed 2,600 kcals•d-1 consisting of 55% carbohydrate, 15% protein, and 30% fat and were instructed to follow their respective Phase I diet (1,200 kcals/d) for 2-days only if they gained 1.35 kg (3 lbs).
Study NCT01271218 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Diet
Description: Participants followed isoenergetic low fat diets with higher protein (HP) or higher carbohydrate (HC) macronutrient content. Participants consumed 1,200 kcals/d for 1-week (Phase I) and 1,600 kcals/d for 9-weeks (Phase II) during a 10-week weight loss period. Participants in the HC diet consumed a diet containing 55% carbohydrate, 15% protein, and 30% fat. Subjects in the HP group consumed a diet containing 7% carbohydrate, 63% protein, and 30% fat during Phase I of the diet and 15% carbohydrate, 55% protein, and 30% fat during Phase II of the diet. The final 4-weeks of the diet (Phase III) served as a weight maintenance period in which participants consumed 2,600 kcals•d-1 consisting of 55% carbohydrate, 15% protein, and 30% fat and were instructed to follow their respective Phase I diet (1,200 kcals/d) for 2-days only if they gained 1.35 kg (3 lbs).
Study NCT01271218 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: All subjects participated in a supervised exercise program three days per week for 14-weeks. Each circuit-style workout consisted of 14 exercises (e.g. elbow flexion/extension, knee flexion/extension, shoulder press/lat pull, hip abductor/adductor, chest press/seated row, horizontal leg press, squat, abdominal crunch/back extension, pec deck, oblique, shoulder shrug/dip, hip extension, side bends and stepping). Participants performed as many repetitions in a 30-s time period. In a continuous, interval fashion, participants performed floor-based callisthenic (e.g. running/skipping in place, arm circles, etc.) exercises on recovery pads for a 30-s time period after each resistance exercise in an effort to maintain a consistent exercise heart rate that corresponded to 60% to 80% of their maximum heart rate.
Study NCT01271218 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: All subjects participated in a supervised exercise program three days per week for 14-weeks. Each circuit-style workout consisted of 14 exercises (e.g. elbow flexion/extension, knee flexion/extension, shoulder press/lat pull, hip abductor/adductor, chest press/seated row, horizontal leg press, squat, abdominal crunch/back extension, pec deck, oblique, shoulder shrug/dip, hip extension, side bends and stepping). Participants performed as many repetitions in a 30-s time period. In a continuous, interval fashion, participants performed floor-based callisthenic (e.g. running/skipping in place, arm circles, etc.) exercises on recovery pads for a 30-s time period after each resistance exercise in an effort to maintain a consistent exercise heart rate that corresponded to 60% to 80% of their maximum heart rate.
Study NCT01560741 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Telemonitoring tools
Description: Patients will go home with telemedicine tools to monitor efficacy and compliance of non-invasive home mechanical ventilation
Study NCT01560741 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Usual Care
Description: The assessment of efficacy and compliance will be monitor at the end of third month. This is the date of the scheduled hospital visit.
Study NCT03719651 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LOCI
Description: LOCI includes training of leaders in general leadership, implementation leadership, and implementation climate.